2019
DOI: 10.1093/icvts/ivz170
|View full text |Cite
|
Sign up to set email alerts
|

Comparative spallation performance of silicone versus Tygon extracorporeal circulation tubing

Abstract: OBJECTIVES Reports ranged from mixed to marginal tubing wear and spallation effects as a complication of roller pumps in cardiopulmonary bypass (CPB). Because the rollers constantly compress part of the tubing, we sought to determine whether circuit materials behave differently under a 3-h simulation of CPB. METHODS Two different tubing materials (silicone and Tygon) were tested with a customized experimental circuit, designe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 16 publications
0
1
0
Order By: Relevance
“…removal of cytokines. [12][13] Third, since no significant associations were found when appraising death risk according to country, center, or institutional volume, it is reasonable to speculate that ECMO technology may be safely applied in all ECMO centers by experienced users applying state of the art techniques and ancillary management and not only in high volume centers, especially when ECMO therapy is implemented with careful optimization of anticoagulation, thus minimizing inflammatory and thrombotic complications leading to microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS). 14 Taken together these findings highlight the current role of ECMO in COVID-19, reassuring on its short-term favorable results even in low-volume centers and in both genders, which may open new perspectives and induce an improvement of World Health Organization interim guidelines.…”
Section: Discussionmentioning
confidence: 99%
“…removal of cytokines. [12][13] Third, since no significant associations were found when appraising death risk according to country, center, or institutional volume, it is reasonable to speculate that ECMO technology may be safely applied in all ECMO centers by experienced users applying state of the art techniques and ancillary management and not only in high volume centers, especially when ECMO therapy is implemented with careful optimization of anticoagulation, thus minimizing inflammatory and thrombotic complications leading to microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS). 14 Taken together these findings highlight the current role of ECMO in COVID-19, reassuring on its short-term favorable results even in low-volume centers and in both genders, which may open new perspectives and induce an improvement of World Health Organization interim guidelines.…”
Section: Discussionmentioning
confidence: 99%